

**BIOLOGICAL TIMEKEEPING**

**Martha U. Gillette, Ph.D.<sup>a,b</sup>, Sabra M. Abbott, M.D., Ph.D.<sup>b,c,d</sup>, and Jennifer M. Arnold<sup>b</sup>**

<sup>a</sup>Alumni Professor of Cell & Developmental Biology and the Neuroscience Program, University of Illinois at Urbana-Champaign, Urbana, IL

<sup>b</sup>Department of Molecular & Integrative Physiology and the College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL

<sup>c</sup>Clinical Fellow in Medicine, Harvard Medical School; and

<sup>d</sup>Medical Resident, Massachusetts General Hospital, Boston, Massachusetts

This work was supported by the following past and present grants from the National Institutes of Health: HL67007, HL086870, HL092571Z ARRA, NS22155, and NS35859 (MUG), F30 NS047802 and GM07143 (SMA), and GM007283 (JMA).

Keywords: biological rhythms, sleep, circadian, suprachiasmatic nucleus

<sup>a</sup>Corresponding author for

Proof and reprints:

Martha U. Gillette, Ph.D.

Dept. of Cell & Developmental Biology

Chemistry & Life Sciences Lab,

University of Illinois

601 S. Goodwin Avenue,

Urbana, IL, U.S.A. 61801

Telephone: 217- 244-1355

fax: 217/ 244-1648

email: [mgillett@life.illinois.edu](mailto:mgillett@life.illinois.edu)

URL: <http://www.life.uiuc.edu/clockworks/>

<sup>b, c, d</sup>Coauthor addresses:

Sabra M. Abbott, M.D., Ph.D.

Department of Internal Medicine

Massachusetts General Hospital

55 Fruit Street

Boston, MA 02114

Telephone: 617-726-2066

email: [smabbott@partners.org](mailto:smabbott@partners.org)

Jennifer M. Arnold

Dept. of Molecular and Integrative Physiology

Chemistry and Life Sciences Lab,

University of Illinois

601 S. Goodwin Avenue,

Urbana, IL, U.S.A. 61801

Telephone: 217-244-1842

email: [jarnol4@illinois.edu](mailto:jarnol4@illinois.edu)

The daily transitions between light and darkness have significantly shaped the evolution of most living species, from unicellular organisms to mammals. Superimposed upon the daily light-dark cycle is a seasonal influence that changes the relative durations of day and night over the course of a year. Be they day-active or night-active, all organisms organize their behaviors in the 24-hour world, adapting to the availability of food and changing temperature, rearing their young, and avoiding predators. To optimize survival, they must be able to anticipate environmental transitions and to adjust to changes in night-length or transition times that may occur.

Adaptation to these needs occurred through the emergence of a circadian system capable of aligning behavioral, physiological, and metabolic processes with this light-dark cycle. The circadian system organizes body systems so that they occur in 24-hour rhythms. Rather than simply reflecting the external day-night cycle, these rhythms in behaviors persist in the absence of exogenous timing cues, such as light, food availability, or social cues. Every organism expresses an endogenous rhythm that varies slightly from 24 h, making it *circadian*, or ‘about a day.’ Uninterrupted, this circadian rhythm persists.

These circadian rhythms can be observed in outputs, such as the patterning of the sleep-wake cycle. In humans, core body temperature is often used as a marker of circadian phase. In addition, numerous endogenous hormones oscillate with a predictable phase relationship to day and night (reviewed by Van Cauter<sup>1</sup>). Hormonal rhythms exhibit complex waveforms due to combined effects of the circadian pacemaker, organismic state, such as activity level, sleep and feeding, and the pulsatile nature of secretion. Nevertheless, clear diurnal patterns of secretion have been reported<sup>2</sup>. Plasma melatonin<sup>3,4</sup>, growth hormone<sup>5</sup>, prolactin<sup>6</sup>, thyrotropin-releasing hormone<sup>7</sup>, luteinizing hormone<sup>8</sup> and leptin<sup>9-11</sup> are all elevated during the night, in antiphase to adrenocorticotrophic hormone and cortisol<sup>12,13</sup>. These oscillations in hormone secretion continue in a constant environment, and, therefore, are clock-regulated. Circadian rhythmicity appears to be present at virtually every level of function studied. In fact, maintenance of a constant *milieu interior* may be a consequence of a balance among rhythmic, mutually opposed control mechanisms<sup>2</sup>.

This review will explain the neurobiology of circadian timekeeping, describing what is known about the master pacemaker for circadian rhythmicity, how various biological systems can provide input to the endogenous biological timing, and how the pacemaker can, in turn, influence the physiology and behavior of the individual. We will discuss how the circadian system can adapt to a changing environment by resetting the circadian clock in the face of a variety of inputs, including changes in light, activity and the sleep-wake cycle. We will then discuss the genetics of circadian time-keeping, highlighting what is currently known about heritable disorders in circadian timing and how circadian genetics have been utilized to study timekeeping. Finally, we will discuss the clock’s role in peripheral tissues.

## **I. THE CIRCADIAN CLOCK**

In mammals, circadian rhythms are regulated by a paired set of nuclei located at the base of the hypothalamus, directly above the optic chiasm, hence their name – the suprachiasmatic nuclei (SCN) (Fig 1). Multiple experiments have demonstrated the role of the SCN as a central pacemaker for circadian rhythms. Lesioning studies found that damage to the SCN disrupts rhythmicity in corticosterone levels, drinking, and wheel

running behavior<sup>14,15</sup>. This provided the initial evidence that the central pacemaker for the mammalian clock lay within the SCN.

In later work, it was found that transplanting fetal SCN tissue into the third ventricle of animals in which the SCN had been lesioned could restore rhythmicity<sup>16</sup>. Furthermore, if fetal SCN tissue from a wild-type hamster was implanted into the third ventricle of a hamster with a genetic alteration that shortened free-running period, the new free-running period resembled that of the SCN donor rather than the host animal. This evidence suggested that not only was the SCN necessary for generating rhythms, but also the period of this rhythmicity was an intrinsic property of the SCN cells—and the presence of SCN was sufficient to drive the rhythms for the entire animal<sup>17</sup>.

In the mouse, each SCN measures approximately 300  $\mu\text{m}$  medial to lateral, 350  $\mu\text{m}$  dorsal to ventral, and spans approximately 600  $\mu\text{m}$  from rostral to caudal end. One SCN contains a total of approximately 10,500 cells<sup>18</sup>. The rodent SCN has several peptidergic subregions (Fig. 1). The central region of the SCN contains small neurons that show positive staining for gastrin-releasing peptide (GRP) colocalized with  $\gamma$ -amino butyric acid (GABA), and the newly discovered peptide, little SAAS<sup>18-21</sup>. The ventrolateral region of the SCN contains neurons that stain predominately for vasoactive intestinal peptide (VIP), but a population of calretinin (CALR) cells is also seen here. The dorsomedial region of the SCN contains larger neurons that contain arginine vasopressin (AVP), met-enkephalin (mENK), and angiotensin II (AII)<sup>18,20,21</sup>. There are topographic connections between all regions of the nucleus, as well as communication between the two nuclei of the animal<sup>22</sup>.

The human SCN is not as compact as the rodent, but has a similar peptidergic organization. The dorsal and medial regions contain neurophysin/vasopressin neurons. The central region contains calbindin, synaptophysin, and VIP neurons, while the ventral and rostral regions contains synaptophysin, calbindin, and substance P<sup>23</sup>.

## **Inputs**

In conjunction with its ability to regulate circadian timing, the SCN is also positioned to receive information about environmental and behavioral states of the animal in order to ensure proper alignment of the circadian clock. This information is conveyed to the SCN by projections from a variety of different brain regions.

One of the most extensively studied inputs to the SCN comes from a subpopulation of retinal ganglion cells whose central projections form the retinohypothalamic tract (RHT). Lesions of the SCN disrupt the development of these neurons<sup>24</sup>, and disruption of the RHT results in an inability to respond to resetting light signals<sup>25,26</sup>. The class of retinal ganglion cells that comprise the RHT contain a blue-light photopigment, melanopsin<sup>27</sup>. These melanopsin-containing cells are photosensitive at the same wavelengths that are most effective for circadian resetting<sup>28</sup>. Additionally, the terminals of the melanopsin-positive retinal ganglion cells colocalize glutamate (GLU) and pituitary adenylate cyclase-activating polypeptide (PACAP)<sup>29</sup>, the neurotransmitters of the RHT<sup>30,31</sup>.

The RHT also sends projections to the thalamic intergeniculate leaflet (IGL), which, in turn, sends projections back to the SCN through the geniculohypothalamic tract (GHT). The GHT contains neuropeptide Y (NPY) and GABA. NPY is believed to be involved in activity-induced phase shifts during the daytime in nocturnal animals, but also appears to be able to modulate light-induced phase shifts<sup>32-34</sup>. However, while the GHT pathway can transmit photic signals, disruption of this pathway does not prevent entrainment<sup>35</sup>.

The SCN also receives serotonergic input, primarily from the median raphe, that is primarily involved in activity-induced phase shifts during the daytime. Activation of the median raphe results in an increase in serotonin (5-HT) release at the SCN<sup>36-38</sup>. 5-HT release also shows a strong circadian release pattern in the SCN, with 5-HT release peaking at CT 14, and 5-hydroxyindole acetic acid (5-HIAA), the major metabolite of 5-HT, peaking at CT 16<sup>39</sup>.

Cholinergic projections to the SCN originate both in the brainstem and basal forebrain in brain nuclei with identified roles in sleep and arousal<sup>40</sup>, and were recently demonstrated to also be present in diurnal animals<sup>41</sup>. Within the brainstem, these cholinergic projections arise from three nuclei. The parabigeminal nucleus (PBg) is considered a satellite region of the superior colliculus, which appears to play a role in generating target-location information as part of saccadic eye-movements<sup>42</sup>. The laterodorsal tegmental (LDTg) and pedunculo pontine tegmental (PPTg) nuclei both are important for regulating the sleep-wake cycle<sup>43</sup>. In the basal forebrain, the substantia innominata (SI) within the nucleus basalis magnocellularis (NBM) in the basal forebrain contributes to arousal and focused attention<sup>44</sup>. The LDTg, PPTg, and NBM are interconnected, and all play roles in regulating the sleep and arousal states of the animal. This would suggest that the cholinergic input to the SCN is providing a signal regarding the sleep and arousal states of the animal, and may provide a link between the sleep-wake cycle and circadian rhythms.

Additional sleep-wake input to the SCN may come from the tuberomammillary nucleus (TMN). Studies have shown histaminergic input to the SCN from the TMN<sup>45</sup>. Histamine is a regulator of the sleep-wake cycle, primarily providing a signal of wakefulness.

## **Outputs**

The SCN exerts its influence on the body primarily at the level of the hypothalamus. Neurons from the ventral regions of the SCN project to the lateral region of the hypothalamic subparaventricular zone (sPVHz), the peri-suprachiasmatic area (PSCN), and the ventral tuberal area (VTU). The dorsal region of the SCN projects to medial preoptic area (MPOA), medial sPVHz, dorsal parvocellular paraventricular nucleus (dPVN), and the dorsal medial hypothalamus (DMH), also all within the hypothalamus<sup>46</sup>. The targets of efferents to the dPVN consist of endocrine neurons, autonomic neurons, or intermediate neurons that potentially serve to integrate a number of hypothalamic signals<sup>47</sup>.

Many SCN projection sites are regulators of sleep and arousal. The DMH projections are especially interesting, as many of these neurons appear to project to neurons containing hypocretin/orexin, a peptide well known for its role in arousal<sup>48,49</sup>. In addition, evidence exists for a multi-synaptic pathway between the SCN and locus coeruleus (LC), an important arousal center in the brain, mediated by orexin<sup>50</sup>, with the DMH as a relay<sup>51</sup>. A minor set of SCN efferents project to the ventrolateral preoptic nucleus (VLPO), a region which, if lesioned, produces prolonged reduction in sleep duration and amplitude<sup>52</sup>. The SCN projects to the paraventricular nucleus (PVT) and intergeniculate leaflet (IGL) of the thalamus. Both nuclei project back to the SCN. The PVT loop is proposed to provide assessment of sleep/arousal states and SCN modulation, whereas the IGL loop is thought to provide the SCN with information from higher, integrative visual centers<sup>53-55</sup>. The PVN appears to act as a relay between the SCN and the amygdala, which may provide a link between the circadian system and affective

disorders<sup>56</sup>. Overall, the SCN appears to be uniquely situated within a network that allows it to interact closely with the regions controlling sleep and arousal states.

## II. CIRCADIAN RESETTING

Despite the circuit-based organization of neural function, there is a consensus that timekeeping is a cellular process<sup>57</sup>. Indeed, the expression of independently-phased circadian firing rhythms from individual neurons dissociated from neonatal rat SCN cultured on an electrode array provides compelling evidence for the cellular nature of this clock<sup>58</sup>. It follows that gating of sensitivity to resetting stimuli and phase resetting must be cellular properties. Moreover, the clock must be able to restrict the range of responses in the cellular repertoire so that activation of select signaling pathways can occur only at the appropriate time in the circadian cycle<sup>59</sup>. We have endeavored to determine how the clock temporally regulates the responsiveness of specific signaling pathways.

In an attempt to define and understand the underlying control mechanisms subserving clock-gated windows of sensitivity, SCN-bearing brain slices are exposed *in vitro* to treatments that activate elements of specific signaling pathways. Treatments are administered at various discrete points in the circadian cycle, and effects on the time-of-peak in the spontaneous rhythm of neuronal activity assessed over the next one or two circadian cycles *in vitro*. If the time-of-peak appears earlier during cycle(s) after treatment compared to controls, the phase of the rhythm is advanced. If the time-of-peak appears later than in controls, then the phase is delayed by the treatment. By assessing the changing relationship between the circadian time of treatment and its effect on phase, a phase-response curve (PRC) can be generated. This relationship graphically presents the temporal pattern of SCN sensitivity to activation of specific signaling pathways and, in fact, defines the window of sensitivity to phase resetting via this pathway. The permanence of the phase shift is examined by evaluating the time of the peak in neuronal activity over one or two days after a treatment. Timing of the peak after experimental reagents are administered at the maximal point of sensitivity is compared with the time of the peak in media-treated controls.

Temporal spheres identified as sensitive to phase resetting via specific first and second messenger pathways coincide with discrete portions of the circadian cycle. In terms of these temporal restrictions, the circadian cycle can be divided into several discrete temporal states, or domains, of the clock: day, night, dusk and dawn<sup>59,60</sup>. These studies not only contribute to defining the properties of the clock's temporal domains, they emphasize the complexity of control that the clock exerts over signal integration and phase resetting within the SCN. These properties have been incorporated into putative clock-gated regulatory pathways. Each will be discussed in the context of the clock domain that is regulated.

Subjective day and night are distinct with respect to their sensitivities and response characteristics. Furthermore, each correlates with discrete periods of sensitivity to specific neurotransmitter systems that are demonstrated to impinge upon this hypothalamic site as evidenced by a large body of neuroanatomical studies<sup>61</sup>. This permits speculation regarding the nature of pathways that gain access to and regulate the biological clock at different points in the circadian cycle. We will now consider, in turn, the major identified domains of clock sensitivity.

## Circadian Clock Regulators

### Daytime

A number of signaling molecules appear to be important in resetting circadian rhythms during the daytime, including 5-HT, PACAP, NPY and GABA (Fig. 2). The majority of these experiments have been performed in nocturnal rodents, so daytime is defined as the time in which the lights are on, and/or the animal is inactive. As a result, the functional context of this regulation seems to be tied to arousal-induced resetting, often referred to as non-photic resetting<sup>62,63</sup>. Non-photic signals cover a wide variety of phenomenon, including sleep deprivation, activity associated with exposure to a novel wheel, or even cage changes. The unifying factor in non-photic signals is that they involve arousal during a time when the animal would normally be inactive.

5-HT is believed to play a role in non-photic, activity-induced phase shifts during the day. Increasing 5-HT in the SCN during subjective day induces an advance in peak electrical firing rate *in vitro* or onset of wheel-running *in vivo*<sup>36,64</sup>. *In vivo*, 5-HT levels in the SCN are increased by electrical stimulation of the dorsal or median raphe<sup>36,65</sup>. Forced wheel-running or sleep deprivation during the day also increases 5-HT in the SCN<sup>66,67</sup>, which suggests a role for 5-HT in non-photic phase-shifting. However, depleting 5-HT from raphe projections does not prevent this non-photic daytime shift<sup>68</sup>, and serotonergic antagonists are not able to attenuate this phase shift<sup>69</sup>, providing mixed evidence for the role of 5-HT. This suggests modulation by additional messengers, possibly neuropeptides.

A second daytime modulator of the SCN clock is the peptide, PACAP. PACAP is not intrinsic to the SCN, but instead is released from the RHT, where it colocalizes with GLU<sup>70</sup>. Levels of PACAP have been found to oscillate throughout the day in SCN samples, which include synaptic terminals of the RHT, but not in other brain regions<sup>71</sup>. If PACAP is applied to the SCN brain slice in micromolar quantities, it elicits an advance in peak neuronal firing during the day, but has little effect during night<sup>29</sup>. *In vivo* findings, however, conflict with this, as the long-term effect of PACAP injection into the SCN seems to be a delay in onset of wheel-running<sup>72</sup>. This conflicting data suggests that further study of PACAP's effects on the clock during the day are warranted.

A third daytime regulator of the clock, NPY, also appears to play a dual role in the SCN, resetting the circadian clock both during the daytime and at night. NPY is released from the GHT, the projection from the IGL to the SCN. When NPY was applied during the daytime either to an SCN brain slice *in vitro*<sup>32</sup> or directly to the SCN *in vivo*<sup>73,74</sup>, it induced a phase advance. Additional *in vivo* studies stimulated the IGL, presumably inducing the release of NPY at the SCN. These stimulations also produced advances in wheel-running behavior during the daytime<sup>75</sup>. Interestingly, it has been found that exposing an animal to light<sup>76</sup> or applying GLU to the brain slice<sup>77</sup> were both capable of blocking the response to daytime application of NPY. The addition of the GABA<sub>A</sub> antagonist, bicuculline, is also capable of inhibiting the effects of NPY<sup>78</sup>, suggesting that the effects of NPY are linked to GABAergic signaling.

One factor that daytime signaling pathways have in common is that they all may be mediated by cyclic adenosine monophosphate (cAMP). In the hypothalamic brain slice, cAMP or cAMP analogs applied during the daytime induce phase advances in the circadian clock, while at night they have little effect<sup>79,80</sup>. In addition, endogenous cAMP is high during late day and late night<sup>81</sup>, suggesting a role for cAMP in the transition periods

between day and night. It can be hypothesized that by increasing cAMP, these daytime resetting signals are moving the animal to a state that resembles late day, thus resetting the clock.

#### *Dawn and Dusk*

The primary resetting signal associated with dawn and dusk is melatonin (Fig. 2). This “hormone of darkness” is produced at night in the absence of light, providing a means by which the animal can measure night-length. Photoperiod is an important measure for animals, such as hamster and sheep, that are seasonally reproductive. Melatonin is produced by the pineal gland, and in lower vertebrates, such as fish, lizards, and some birds, the pineal is actually the primary regulator of circadian rhythms, rather than the SCN. However, in mammals this timekeeping mechanism has moved to the SCN, as demonstrated by the fact that removal of the pineal does not significantly disrupt circadian rhythms of rats<sup>82</sup>.

While the pineal is not necessary for maintenance of mammalian circadian rhythms, it is possible to entrain free-running rats with daily injections of melatonin. Entrainment appears to work best if the melatonin injections are timed to occur shortly before the onset of the animal’s active period. This entrainment appears to be working through the SCN, as lesioning the SCN, but not the pineal, abolishes the ability of a rat to entrain to melatonin injections<sup>83</sup>.

Evidence that melatonin can entrain circadian rhythms led to a number of studies looking at the direct effect of melatonin on the SCN. Melatonin application immediately before dusk in rat or hamster tissue *in vitro* decreases SCN activity, measured by 2-deoxy-[1-<sup>14</sup>C]glucose (2-DG) uptake or neuronal firing rate<sup>84-86</sup>. Additionally, melatonin applied to SCN brain slices at either dawn or dusk advances the peak in neuronal firing. Melatonin is ineffective when applied at other times of day<sup>87,88</sup>. This resetting pattern is reproduced by direct activation of protein kinase C (PKC), and can be blocked by inhibitors of PKC, suggesting that PKC is a downstream component of this resetting pathway<sup>88</sup>. In addition, melatonergic resetting is inhibited with antagonists specific for the MT-2 type melatonin receptor<sup>89</sup>. In humans, circadian sensitivity to melatonin also occurs at dawn and dusk, but the effect is to advance the circadian system at dusk and to delay it at dawn, opposite to the effects of light at night.

#### *Nighttime*

In the nighttime domain there are two known key players, GLU and acetylcholine (ACh), as well as a number of modulatory substances associated with these signals (Fig. 2). As was discussed previously, considerable evidence supports GLU as the neurochemical signal transmitting photic stimuli from the retina to the SCN, but the functional context of the cholinergic resetting signal is still unknown.

The GLU signaling pathway is similar to many of the pathways that already have been discussed in that it resets the circadian clock at a discrete time of day and in a specific direction. The GLU signaling pathway can either advance or delay the clock, depending on what time of day the signal is presented<sup>30,90</sup>. The GLU resetting pathway has been demonstrated both *in vitro* and *in vivo* to be mediated through an N-methyl-D-aspartate (NMDA) receptor-mediated rise in intracellular calcium, followed by nitric oxide synthase (NOS) induction and resultant production of nitric oxide (NO)<sup>30,91-94</sup>. Beyond this point, the early and late night pathways diverge. During the early night GLU induces delays in the circadian clock through ryanodine receptor (RyR)-mediated calcium release<sup>95</sup>. GLU exposure

during the late night, however, advances the circadian clock through a cyclic guanosine monophosphate/protein kinase G (cGMP/PKG) signaling cascade followed by cAMP response element-binding protein (CREB)-activated transcription<sup>95-97</sup>.

While GLU alone is capable of resetting circadian rhythms, there are many substances that modulate this resetting. These can be divided into two categories: those that decrease the amplitude of the phase-resetting effect of GLU during both the early and late night, which include NPY and GABA<sup>33,64</sup>, and those that have differing effects on GLU-induced phase shifts, depending on what time of night they are applied.

This second category of time-dependent modulators include 5-HT and PACAP. If animals are depleted of 5-HT, they show increased phase delays in response to light<sup>98,99</sup>. Co-application of a PACAP antagonist, however, either *in vitro* or *in vivo*, decreases the phase delay seen with application in early night, and when applied during late night, increases the amplitude of the phase advance in both rat and hamster<sup>100,101</sup>. When PACAP is administered in conjunction with GLU in early night, it increases the delays, but in late night it decreases phase advances. This is similar to the effects seen following application of cAMP analogs to the hypothalamic brain slice, suggesting that the effects of PACAP may be mediated via a cAMP pathway<sup>102</sup>.

The role of ACh in resetting circadian rhythms has been unclear, with much of the confusion arising from the fact that its effects vary depending on the site of application. The first evidence that ACh might play a role in resetting the circadian clock came in 1979, when Zatz and Brownstein examined whether pharmacological manipulation of the SCN could affect circadian rhythms. It was found that injections of the ACh agonist carbachol into the lateral ventricle of Sprague-Dawley rats at CT 15 caused phase delays that were similar to, but not as large as, the phase delays produced by light<sup>103</sup>. Carbachol injections into the lateral ventricle were also later repeated in mice<sup>104</sup> and hamsters<sup>105</sup>, where it was found that administration of carbachol during early night caused phase delays, while late night administration caused phase advances.

This pattern of sensitivity and response is similar to that previously demonstrated in response to light or GLU. Support for the involvement of ACh in the light response came from studies looking at ACh levels in the rat SCN using a radioimmunoassay (RIA)<sup>106</sup>. Using this technique, no significant oscillation in ACh levels was found under constant conditions, but light pulses administered at CT 14 were found to increase ACh levels in the SCN. However, only one time-point was examined, so it is not known whether this increase was simply a response to exposure to light or if there was actually a circadian pattern to the light-stimulated release. The implication of these studies, however, is that ACh might be the primary neurotransmitter providing the signal of light to the clock.

However, significant evidence began to emerge indicating that ACh was not likely to be the primary signal of light. First of all, whereas it had previously been determined that the RHT transmitted the signal of light from the eye to the SCN, it was found that choline acetyltransferase (ChAT) was not present in this projection<sup>107</sup>, making it anatomically unlikely that ACh was the primary neurotransmitter involved in this signal. This evidence might warrant reconsideration, however, as recent studies have found an alternative splice variant of ChAT present in ganglion cells that was not picked up using previous antibodies<sup>108</sup>.

Additional evidence against ACh being the signal of light came from experiments that found intracerebroventricular (*icv*) injections of hemicholinium, which significantly depletes ACh stores in the brain, did



not block the ability of the animal to phase shift in response to light<sup>109</sup>. There was also evidence that injecting NMDA receptor antagonists could block carbachol induced phase shifts, suggesting that although ACh may play a role in the light response, it must be upstream of a glutamatergic signal<sup>110</sup>. Finally, Liu and Gillette<sup>111</sup>, using extracellular recording *in vitro*, found that microdrop applications of carbachol directly to the SCN caused only phase advances, regardless of whether the carbachol was applied early or late in the night.

In an attempt to explain these contradicting data, it was hypothesized by our lab that the dual response pattern of the SCN to cholinergic stimulation was a result of the location of application. Note that in the initial *in vivo* studies, carbachol was injected into the lateral or third ventricle, where the drug could have a diffuse effect, while in the *in vitro* studies carbachol was applied in microdrops directly to the SCN. As was predicted, if the *in vivo* experiments were performed by injecting carbachol directly into the SCN rather than into the ventricle, a phase response pattern similar to that observed in the *in vitro* experiments using microdrop applications resulted<sup>112</sup>. This evidence suggests that ACh has at least two different effects on the circadian clock, depending upon the site of application. There is an indirect response, working through ventricular pathways, that is likely upstream of a glutamatergic signal, and a direct response that is mediated by the M<sub>1</sub>AChR<sup>113</sup>. Based on the anatomical studies looking at cholinergic projections to the SCN that originate in the LDTg and PPTg, as well as the (NBM), the current hypothesis is that this cholinergic signal may be involved in linking the sleep-wake and circadian cycles together.

### III. GENETICS OF CIRCADIAN RHYTHMS

Much research effort has focused on determining how a biological system keeps 24-hour time. With the discovery that single, dispersed cells can exhibit circadian rhythms<sup>114</sup>, the focus turned towards understanding cellular processes that generate a near 24-hour timebase. A molecular clockwork generates a ~24-hour rhythm through a feedback cycle involving a set of core clock genes, their mRNAs, and proteins<sup>115,116</sup>. This cycle consists of a set of interconnected positive and negative feedback loops, and their regulatory elements. Positive elements, which include *Clock* and *Bmal1*, are transcribed into mRNA, which is then translated into proteins that heterodimerize and are translocated into the nucleus. In the nucleus, they activate continued transcription of their own genes, as well as activating transcription of negative elements. The negative elements, which include *Period*, *Cryptochrome* and *Rev-erba*, are then transcribed and translated. Proteins of the negative elements also associate in complexes and are translocated to the nucleus, where they feed back to inhibit transcription of the positive elements<sup>115,116</sup>. Additional genes that have been proposed to be involved in the circadian clock include *Rora*<sup>117</sup>, *Timeless (Tim)*<sup>118</sup>, *Dec1* and *Dec2*<sup>119</sup>, and more recently *SIRT1*<sup>37,120,121</sup>. These feedback loops are further affected by regulatory enzymes, including casein kinase 1 epsilon (CKIε) and glycogen synthase kinase (GSK)<sup>122-124</sup>, and small intracellular regulatory molecules, such as calcium and cAMP with established roles in signal transduction<sup>37,125</sup>. The cycle of these feedback loops takes approximately 24 hours to complete, providing a means by which cells can maintain a circadian rhythm.

Core clock elements have been found to play a critical role in human sleep disorders. For example, inherited forms of advanced sleep phase syndrome (ASPS) have been associated with a mutation in the *Per2* gene that interferes with a normal phosphorylation site of CKIδ/ε<sup>126</sup> or with a mutation in CKIδ<sup>127</sup>. Delayed sleep phase

syndrome (DSPS), on the other hand, has been found in some cases to be associated with a specific polymorphism of hPER3<sup>37,128,129</sup>. PER3 expression patterns in human leukocytes correlate with sleep-wake timing, particularly in those individuals with a preference for morningness<sup>130</sup>. Finally, morningness or eveningness preferences have been associated with polymorphisms of the human *Clock* gene<sup>37,131,132</sup>.

The clock genes have proven useful for studying rhythms as well. Several of these genes, including *Bmall* and two *Per* genes, have been fused to reporter molecules, such as green fluorescent protein (GFP) and firefly luciferase, which enables study of the reporter as a marker of the transcription or translation of the gene. Both by transfecting cell cultures with a construct containing one of these fusion genes<sup>133-136</sup> and by creating transgenic rodents that express these fusion products<sup>137-140</sup>, new insights in clock dynamics have emerged. Among the most surprising is that all cells express them in a circadian pattern, even in dispersed cell culture. This established that circadian clocks are components of nearly all cells.

#### IV. MOLECULAR CLOCKS IN DIVERSE MAMMALIAN CELLS

Although the SCN is necessary as the central circadian pacemaker, the discovery of autonomous clocks driven by oscillations in clock genes focused attention on extra-SCN clocks. Some non-SCN tissue, such as the mammalian pineal gland<sup>141</sup> and retina<sup>142</sup>, express circadian oscillations in metabolites or melatonin when cultured independently. The first oscillations of clock genes outside of the SCN were found using a Rat-1 fibroblast cell line. These immortalized cells express clock gene mRNAs, such as *rev-erba*, *per1*, and *per2*, which oscillate in cell culture with a period near 24 hours<sup>143</sup>. When primary mouse embryonic fibroblasts also showed clock gene oscillation, the possibility was raised that individual cells throughout the body might express the molecular components of a clock<sup>135,144-147</sup>.

With the advent of clock gene reporter systems, studies emerged supporting the evidence that peripheral, non-SCN tissues in the body contain functional clocks. The olfactory bulb oscillates in a transgenic rat that contains the promoter sequence for *mPer1* linked to luciferase<sup>139</sup>. The olfactory bulb maintains rhythmic luciferase expression when the SCN is surgically ablated<sup>148</sup>, the rat is made arrhythmic by placing it in constant light<sup>149</sup>, or when the olfactory bulb is isolated in tissue culture<sup>148,150</sup>. Many brain regions<sup>150,151</sup> and peripheral tissues, including skeletal muscle, liver, and lung, also exhibit oscillations in clock genes, which remain rhythmic in culture for up to a week<sup>139,151,152</sup>.

Further technical advancements lead to the creation of a mouse containing a reporter of the PER2 protein fused to luciferase (PER2::LUC). This knock-in approach, which enabled direct assessment of PER2 protein expression, is more physiological than transcriptional reporters and allows for study of peripheral tissues in culture for much longer periods<sup>140</sup>. Many tissues from this mouse, including cornea, kidney, liver, lung, pituitary, and tail, show clear, robust oscillations in PER2::LUC for up to 1 week *in vitro*, although SCN, liver, and lung tissues continue to show circadian rhythms for up to 3 weeks. Unexpectedly, tissue taken from SCN-lesioned mice 3-5 weeks following surgery still demonstrated robust near-24-hour rhythms in cellular luciferase luminescence, though the phasing of the rhythms were widely dispersed amongst the various tissues<sup>140</sup>. Individual fibroblasts from these PER2::LUC mice also maintain an oscillation in culture<sup>135</sup>. Experiments carried out with these reporter animals,

along with those carried out using the transcriptional reporters, demonstrate that nearly all peripheral cells in the body and some in the brain contain the molecular machinery of a functional circadian clock.

## V. COUPLING OF CENTRAL AND PERIPHERAL CLOCKS

The above discussion emphasizes the myriad individual oscillating clocks in the body. In animals with a functional SCN, these clocks are aligned so that each individual tissue maintains a stable phase relationship to the SCN so that clock genes are expressed at the same time each day. When SCN rhythmicity is removed or the phase is shifted, the various tissues maintain their individual circadian rhythms, but they quickly fall out of phase with each other<sup>139,140,153</sup>. This indicates a hierarchical relationship in which the SCN is the master regulator that synchronizes and aligns the rest of the body's clocks. Much study of the coupling of extra-SCN clocks to the central pacemaker has been undertaken, and several examples will be highlighted in the following discussion.

The earliest SCN isolation studies established the SCN's role as the master clock, but these studies also hint at the various means by which this clock exerts control over peripheral structures. When the SCN is surgically isolated from the rest of the hypothalamus in rats, serum corticosterone oscillations continue, while locomotor rhythms are lost<sup>154</sup>. Additionally, surgical cuts to rodent brains between the SCN and PVN abolish reproductive rhythms in hamsters, but rhythmic locomotor activity is maintained in hamsters<sup>155,156</sup> and rats<sup>157</sup>. These findings provide early evidence for both synaptic coupling of SCN to output tissues, as well as the possibility that humoral signals entrain peripheral tissues. This idea was furthered by transplant studies in which an encapsulated fetal SCN is transplanted into an animal with an SCN lesion. Fenestrations in the encapsulating polymer were too small to permit neurite passage, and, indeed, no neural connectivity to the recipient brain could be found. The transplant restores locomotor, feeding, drinking, body temperature, and sleep/wake, but not endocrine, rhythms to the lesioned animal<sup>158</sup>. Clearly, some non-SCN rhythms require physical connections and some do not.

Many rhythm-generating tissues are coupled to the SCN by synaptic connections. Anatomical studies have shown SCN projections that extend to several hypothalamic nuclei, including the organum vasculosum of lamina terminalis (OVLT), medial preoptic area, and PVN, seemingly forming direct synapses with gonadotropin-releasing hormone (GnRH) and corticotropin-releasing hormone (CRH) neurons in these regions<sup>159-161</sup>. Additionally, the neuronal networks connecting the SCN to the IGL and PVT of the thalamus provide the SCN and these sleep/arousal modulatory regions with bi-directional communication<sup>53-55</sup>.

The SCN is one of many regulators of opposing sympathetic and parasympathetic autonomic signals to peripheral organs. Anatomical studies using retrograde tracers injected into peripheral organs, such as liver, adrenal gland, pancreas, and adipose tissue, demonstrate a multi-synaptic pathway connecting these tissues to autonomic centers in the spinal cord, brain stem, PVN and DMH, and finally, to the SCN and other hypothalamic regions<sup>162-165</sup>. Discriminative tracing of either sympathetic or parasympathetic tracts identify SCN neurons in overlapping areas of the nucleus, but these neurons seem to be involved in signaling to one or the other of these pathways<sup>163,164</sup>. Light from the external environment can affect these two pathways through SCN-mediated control. For example, exposure of rats to light at night results in increased sympathetic activity, but suppression of parasympathetic activity. When the SCN is abolished, this effect is lost<sup>166</sup>. Also, heart rate decreases after light exposure at night in a nocturnal rodent, whereas SCN-lesioned animals do not exhibit this response<sup>167</sup>. Clearly, the SCN plays a role in modulating

autonomic signals to the periphery, but it works in concert with many other regions of the brain, including those regulating body temperature, metabolism, reproductive state, and other physiologic functions.

A growing body of evidence supports a role for humoral signaling in the coupling of rhythms between the SCN and other regions. In brain-slice cultures containing PVN tissue, an electrical rhythm emerges in the PVN only after co-culture with an SCN brain slice. The lack of neuronal connections between the two slices *in vitro* strongly supports a diffusible factor as cause of the electrical oscillation of the PVN<sup>168</sup>. Additionally, parabiosis connecting the circulatory system of an intact mouse to that of a SCN-lesioned mouse indicates that diffusible signals from the intact animal can entrain peripheral tissue in the lesioned recipient. Peripheral rhythms of clock gene expression are restored after parabiosis in kidney and liver<sup>169</sup>. Co-culturing functional SCN tissue with peripheral cells or tissue induces rhythms in these cells that follow the SCN under culture conditions that prevent synaptic connections<sup>146,170,171</sup>.

These studies indicate that diffusible signals can modulate rhythms between tissues. Neuropeptides are abundant in the SCN, and are good candidates for humoral signals. As described previously, major neuropeptides found in the SCN include VIP, GRP, little SAAS, and AVP, among others. These peptides are released from the SCN in a circadian fashion<sup>20,172,173</sup>, and each has been implicated in a physiological role in some aspect of circadian biology<sup>20,172,174-180</sup>. Identification of the diffusible signals that couple other tissues to the SCN is the current subject of intense study, with high therapeutic potential.

Another role for diffusible factors from the SCN appears to be to provide a signal inhibitory to activity. Two candidate factors for communicating such signals include transforming growth factor- $\alpha$  (TGF- $\alpha$ ) and prokineticin 2 (PK2). Under normal conditions, TGF- $\alpha$  peptide is expressed rhythmically in the SCN with a peak during the animal's inactive period, and a trough during the active period. When infused continuously into the ventricles, TGF- $\alpha$  fully inhibits locomotor activity. Conversely, mice lacking the cognate receptor, epidermal growth factor (EGF) receptor, are unable to respond to TGF- $\alpha$  and show an excessive amount of daytime activity<sup>181</sup>. PK2 also is expressed rhythmically in the SCN, again showing peak expression during the animal's inactive period, and can inhibit locomotor activity when infused continuously<sup>182</sup>. This suggests a role for output signals from the SCN in promoting an inactive state that would be permissive for sleep.

Some tissues appear to require both synaptic and humoral signals to synchronize to the SCN. When autonomic nerve connections to the liver are severed, plasma insulin and corticosterone levels remain rhythmic, but plasma glucose levels do not<sup>183</sup>. However, liver tissue from an SCN-lesioned mouse with surgical parabiosis to an intact animal recovers and continues to maintain rhythmicity from that point onward<sup>169</sup>. This suggests that control of liver timing requires both neuronal and diffusible signals that coordinate separate physiological functions. Dissecting the intricacies of circadian regulation among peripheral tissues will require careful study.

Coupling of the SCN to peripheral targets, regardless of the manner of this connection, has important implications for health. This interaction allows for synchronization of internal systems to environmental light signals, both on a day-by-day basis and to adjust the animal to seasonal changes. Modern human activities, such as shift work and transcontinental flight, result in significant desynchronization of the central internal clock and various body tissues. This circadian disarray can have dire consequences for human health, including increased risks of

various cancers, reproductive health, stroke, metabolic syndrome, cardiovascular disease<sup>184-186</sup>, and overall mortality in aged individuals<sup>187</sup>.

#### **IV. CONCLUSION**

Circadian rhythms, the near 24-hour oscillations in brain and body functions, such as core body temperature, hormone release, and the sleep-wake cycle, are embedded in the physiology of cells and tissues. The master pacemaker regulating these rhythms, the suprachiasmatic nucleus (SCN) in the hypothalamus, is optimally situated to receive input about environmental light, sleep-wake state and activity status. It can be reset in response to changes in environmental conditions and internal state. These stimuli, in turn, provide output signals to regulate the timing of rest/activity and behavioral cycles. The core mechanisms providing this timekeeping property are provided through transcription/translation feedback loops, consisting of both positive and negative elements, coupled with other intracellular elements associated with signaling events. Clock gene proteins are now being utilized as molecular tools to further study clocks in all tissues, and how the SCN synchronizes and aligns these various body clocks to environmental cycles and imposed work schedules. Circadian rhythm sleep disorders as well as sleep phenotypes are correlated with abnormalities in the genes regulating circadian rhythms. Internal desynchrony of peripheral tissues and the SCN can have negative consequences for human health and longevity. Research to date has revealed surprising complexity in the ordering of body functions. Much remains to be discovered regarding the roles of the SCN and peripheral clocks in coordinating the brain and body in health and disease.

**ACKNOWLEDGEMENTS:** The authors gratefully recognize present and past support from the National Institutes of Health: HL67007, HL086870, HL092571Z ARRA, NS22155, and NS35859 (MUG), F30 NS047802 and GM07143 (SMA), and GM007283 (JMA).

#### **REFERENCES**

1. Van Cauter E. Diurnal and ultradian rhythms in human endocrine function: A minireview. *Horm Res* 1990;34:45-53.
2. Schwartz WJ. A clinician's primer on the circadian clock: Its localization, function, and resetting. *Adv Intern Med* 1993;38:81-106.
3. Arendt J, Minors DS, Waterhouse JM (eds). *Biological rhythms in clinical practice*. Bristol, England: John Wright; 1989. p 299.
4. Van Cauter E, Turek FW. Endocrine and other biological rhythms. In: DeGroot JL, editor: (eds). *Textbook of endocrinology*. Philadelphia: W.B. Saunders; 1995. pp 2487-548.
5. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. *J Clin Invest* 1968;47:2079-90.
6. Van Cauter E, L'Hermite M, Copinschi G, et al. Quantitative analysis of spontaneous variations of plasma prolactin in normal man. *Am J Physiol* 1981;241:E355-63.
7. van Coevorden A, Laurent E, Decoster C, et al. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. *J Clin Endocrinol Metab* 1989;69:177-85.
8. Kapen S, Boyar R, Hellman L, et al. The relationship of luteinizing hormone secretion to sleep in women during the early follicular phase: Effects of sleep reversal and a prolonged three-hour sleep-wake schedule. *J Clin Endocrinol Metab* 1976;42:1031-40.
9. Licinio J, Mantzoros C, Negrao AB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat Med* 1997;3:575-9.

10. Licinio J, Negrao AB, Mantzoros C, et al. Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. *Proc Natl Acad Sci U S A* 1998;95:2541-6.
11. Sinha MK, Ohannesian JP, Heiman ML, et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest* 1996;97:1344-7.
12. Lejeune-Lenain C, Van Cauter E, Desir D, et al. Control of circadian and episodic variations of adrenal androgens secretion in man. *J Endocrinol Invest* 1987;10:267-76.
13. Weitzman ED, Zimmerman JC, Czeisler CA, et al. Cortisol secretion is inhibited during sleep in normal man. *J Clin Endocrinol Metab* 1983;56:352-8.
14. Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. *Brain Res* 1972;42:201-6.
15. Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. *Proc Natl Acad Sci U S A* 1972;69:1583-6.
16. Drucker-Colin R, Aguilar-Roblero R, Garcia-Hernandez F, et al. Fetal suprachiasmatic nucleus transplants: Diurnal rhythm recovery of lesioned rats. *Brain Res* 1984;311:353-7.
17. Ralph MR, Foster RG, Davis FC, et al. Transplanted suprachiasmatic nucleus determines circadian period. *Science* 1990;247:975-8.
18. Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: Retinal innervation, intrinsic organization and efferent projections. *Brain Res* 2001;916:172-91.
19. Antle MC, Silver R. Orchestrating time: Arrangements of the brain circadian clock. *Trends Neurosci* 2005;28:145-51.
20. Atkins N, Jr., Mitchell JW, Romanova EV, et al. Circadian integration of glutamatergic signals by little saas in novel suprachiasmatic circuits. *PLoS One* 2010;5:e12612.
21. Morin LP. Scn organization reconsidered. *J Biol Rhythms* 2007;22:3-13.
22. Moore RY, Speh JC, Leak RK. Suprachiasmatic nucleus organization. *Cell Tissue Res* 2002;309:89-98.
23. Mai JK, Kedziora O, Teckhaus L, et al. Evidence for subdivisions in the human suprachiasmatic nucleus. *J Comp Neurol* 1991;305:508-25.
24. Mosko S, Moore RY. Retinohypothalamic tract development: Alteration by suprachiasmatic lesions in the neonatal rat. *Brain Res* 1979;164:1-15.
25. Johnson RF, Moore RY, Morin LP. Loss of entrainment and anatomical plasticity after lesions of the hamster retinohypothalamic tract. *Brain Res* 1988;460:297-313.
26. Rusak B. Neural mechanisms for entrainment and generation of mammalian circadian rhythms. *Fed Proc* 1979;38:2589-95.
27. Hattar S, Lucas RJ, Mrosovsky N, et al. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. *Nature* 2003;424:76-81.
28. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science* 2002;295:1070-3.
29. Hannibal J, Ding JM, Chen D, et al. Pituitary adenylate cyclase-activating peptide (pacap) in the retinohypothalamic tract: A potential daytime regulator of the biological clock. *J Neurosci* 1997;17:2637-44.
30. Ding JM, Chen D, Weber ET, et al. Resetting the biological clock: Mediation of nocturnal circadian shifts by glutamate and no. *Science* 1994;266:1713-7.
31. Mintz EM, Marvel CL, Gillespie CF, et al. Activation of nmda receptors in the suprachiasmatic nucleus produces light-like phase shifts of the circadian clock in vivo. *J Neurosci* 1999;19:5124-30.
32. Medanic M, Gillette MU. Suprachiasmatic circadian pacemaker of rat shows two windows of sensitivity to neuropeptide y in vitro. *Brain Res* 1993;620:281-6.
33. Yannielli PC, Harrington ME. Neuropeptide y applied in vitro can block the phase shifts induced by light in vivo. *Neuroreport* 2000;11:1587-91.
34. Yannielli PC, Harrington ME. The neuropeptide y y5 receptor mediates the blockade of "Photic-like" Nmda-induced phase shifts in the golden hamster. *J Neurosci* 2001;21:5367-73.
35. Reghunandanan V, Reghunandanan R, Singh PI. Neurotransmitters of the suprachiasmatic nucleus: Role in the regulation of circadian rhythms. *Prog Neurobiol* 1993;41:647-55.
36. Glass JD, DiNardo LA, Ehlen JC. Dorsal raphe nuclear stimulation of scn serotonin release and circadian phase-resetting. *Brain Res* 2000;859:224-32.
37. Imaizumi T, Kay SA, Schroeder JI. Circadian rhythms. Daily watch on metabolism. *Science* 2007;318:1730-1.

38. van den Pol AN, Tsujimoto KL. Neurotransmitters of the hypothalamic suprachiasmatic nucleus: Immunocytochemical analysis of 25 neuronal antigens. *Neuroscience* 1985;15:1049-86.
39. Barassin S, Raison S, Saboureau M, et al. Circadian tryptophan hydroxylase levels and serotonin release in the suprachiasmatic nucleus of the rat. *Eur J Neurosci* 2002;15:833-40.
40. Bina KG, Rusak B, Semba K. Localization of cholinergic neurons in the forebrain and brainstem that project to the suprachiasmatic nucleus of the hypothalamus in rat. *J Comp Neurol* 1993;335:295-307.
41. Castillo-Ruiz A, Nunez AA. Cholinergic projections to the suprachiasmatic nucleus and lower subparaventricular zone of diurnal and nocturnal rodents. *Brain Res* 2007;1151:91-101.
42. Cui H, Malpeli JG. Activity in the parabigeminal nucleus during eye movements directed at moving and stationary targets. *J Neurophysiol* 2003;89:3128-42.
43. Deurveilher S, Hennevin E. Lesions of the pedunculopontine tegmental nucleus reduce paradoxical sleep (ps) propensity: Evidence from a short-term ps deprivation study in rats. *Eur J Neurosci* 2001;13:1963-76.
44. Semba K. Multiple output pathways of the basal forebrain: Organization, chemical heterogeneity, and roles in vigilance. *Behav Brain Res* 2000;115:117-41.
45. Michelsen KA, Lozada A, Kaslin J, et al. Histamine-immunoreactive neurons in the mouse and rat suprachiasmatic nucleus. *Eur J Neurosci* 2005;22:1997-2004.
46. Leak RK, Moore RY. Topographic organization of suprachiasmatic nucleus projection neurons. *J Comp Neurol* 2001;433:312-34.
47. Kalsbeek A, Buijs RM. Output pathways of the mammalian suprachiasmatic nucleus: Coding circadian time by transmitter selection and specific targeting. *Cell Tissue Res* 2002;309:109-18.
48. Abrahamson EE, Leak RK, Moore RY. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. *Neuroreport* 2001;12:435-40.
49. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci U S A* 1998;95:322-7.
50. Gompf HS, Aston-Jones G. Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity. *Brain Res* 2008;1224:43-52.
51. Aston-Jones G, Chen S, Zhu Y, et al. A neural circuit for circadian regulation of arousal. *Nat Neurosci* 2001;4:732-8.
52. Chou TC, Bjorkum AA, Gaus SE, et al. Afferents to the ventrolateral preoptic nucleus. *J Neurosci* 2002;22:977-90.
53. Buijs RM, Hou YX, Shinn S, et al. Ultrastructural evidence for intra- and extranuclear projections of gabaergic neurons of the suprachiasmatic nucleus. *J Comp Neurol* 1994;340:381-91.
54. Moga MM, Weis RP, Moore RY. Efferent projections of the paraventricular thalamic nucleus in the rat. *J Comp Neurol* 1995;359:221-38.
55. Morin LP. The circadian visual system. *Brain Res Brain Res Rev* 1994;19:102-27.
56. Peng ZC, Bentivoglio M. The thalamic paraventricular nucleus relays information from the suprachiasmatic nucleus to the amygdala: A combined anterograde and retrograde tracing study in the rat at the light and electron microscopic levels. *J Neurocytol* 2004;33:101-16.
57. Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: Cell autonomy and network properties. *Annu Rev Physiol* 72:551-77.
58. Walsh IB, van den Berg RJ, Rietveld WJ. Ionic currents in cultured rat suprachiasmatic neurons. *Neuroscience* 1995;69:915-29.
59. Gillette MU. Regulation of entrainment pathways by the suprachiasmatic circadian clock: Sensitivities to second messengers. *Prog Brain Res* 1996;111:121-32.
60. Gillette MU, Mitchell JW. Signaling in the suprachiasmatic nucleus: Selectively responsive and integrative. *Cell Tissue Res* 2002;309:99-107.
61. Moga MM, Moore RY. Putative excitatory amino acid projections to the suprachiasmatic nucleus in the rat. *Brain Res* 1996;743:171-7.
62. Antle MC, Mistlberger RE. Circadian clock resetting by sleep deprivation without exercise in the syrian hamster. *J Neurosci* 2000;20:9326-32.
63. Reeb SG, Mrosovsky N. Effects of induced wheel running on the circadian activity rhythms of syrian hamsters: Entrainment and phase response curve. *J Biol Rhythms* 1989;4:39-48.
64. Medanic M, Gillette MU. Serotonin regulates the phase of the rat suprachiasmatic circadian pacemaker in vitro only during the subjective day. *J Physiol* 1992;450:629-42.
65. Dudley TE, Dinardo LA, Glass JD. In vivo assessment of the midbrain raphe nuclear regulation of serotonin release in the hamster suprachiasmatic nucleus. *J Neurophysiol* 1999;81:1469-77.

66. Dudley TE, DiNardo LA, Glass JD. Endogenous regulation of serotonin release in the hamster suprachiasmatic nucleus. *J Neurosci* 1998;18:5045-52.
67. Grossman GH, Mistlberger RE, Antle MC, et al. Sleep deprivation stimulates serotonin release in the suprachiasmatic nucleus. *Neuroreport* 2000;11:1929-32.
68. Bobrzynska KJ, Vrang N, Mrosovsky N. Persistence of nonphotic phase shifts in hamsters after serotonin depletion in the suprachiasmatic nucleus. *Brain Res* 1996;741:205-14.
69. Antle MC, Marchant EG, Niel L, et al. Serotonin antagonists do not attenuate activity-induced phase shifts of circadian rhythms in the syrian hamster. *Brain Res* 1998;813:139-49.
70. Hannibal J, Moller M, Ottersen OP, et al. Pacap and glutamate are co-stored in the retinohypothalamic tract. *J Comp Neurol* 2000;418:147-55.
71. Fukuhara C, Suzuki N, Matsumoto Y, et al. Day-night variation of pituitary adenylate cyclase-activating polypeptide (pacap) level in the rat suprachiasmatic nucleus. *Neurosci Lett* 1997;229:49-52.
72. Piggins HD, Marchant EG, Goguen D, et al. Phase-shifting effects of pituitary adenylate cyclase activating polypeptide on hamster wheel-running rhythms. *Neurosci Lett* 2001;305:25-8.
73. Albers HE, Ferris CF. Neuropeptide y: Role in light-dark cycle entrainment of hamster circadian rhythms. *Neurosci Lett* 1984;50:163-8.
74. Huhman KL, Albers HE. Neuropeptide y microinjected into the suprachiasmatic region phase shifts circadian rhythms in constant darkness. *Peptides* 1994;15:1475-8.
75. Rusak B, Meijer JH, Harrington ME. Hamster circadian rhythms are phase-shifted by electrical stimulation of the geniculo-hypothalamic tract. *Brain Res* 1989;493:283-91.
76. Biello SM, Mrosovsky N. Blocking the phase-shifting effect of neuropeptide y with light. *Proc Biol Sci* 1995;259:179-87.
77. Biello SM, Golombek DA, Harrington ME. Neuropeptide y and glutamate block each other's phase shifts in the suprachiasmatic nucleus in vitro. *Neuroscience* 1997;77:1049-57.
78. Huhman KL, Babagbemi TO, Albers HE. Bicuculline blocks neuropeptide y-induced phase advances when microinjected in the suprachiasmatic nucleus of syrian hamsters. *Brain Res* 1995;675:333-6.
79. Gillette MU, Prosser RA. Circadian rhythm of the rat suprachiasmatic brain slice is rapidly reset by daytime application of camp analogs. *Brain Res* 1988;474:348-52.
80. Prosser RA, Gillette MU. The mammalian circadian clock in the suprachiasmatic nuclei is reset in vitro by camp. *J Neurosci* 1989;9:1073-81.
81. Prosser RA, Gillette MU. Cyclic changes in camp concentration and phosphodiesterase activity in a mammalian circadian clock studied in vitro. *Brain Res* 1991;568:185-92.
82. Cheung PW, McCormack CE. Failure of pinealectomy or melatonin to alter circadian activity rhythm of the rat. *Am J Physiol* 1982;242:R261-4.
83. Cassone VM, Chesworth MJ, Armstrong SM. Entrainment of rat circadian rhythms by daily injection of melatonin depends upon the hypothalamic suprachiasmatic nuclei. *Physiol Behav* 1986;36:1111-21.
84. Cassone VM, Roberts MH, Moore RY. Effects of melatonin on 2-deoxy-[1-14c]glucose uptake within rat suprachiasmatic nucleus. *Am J Physiol* 1988;255:R332-7.
85. Margraf RR, Lynch GR. An in vitro circadian rhythm of melatonin sensitivity in the suprachiasmatic nucleus of the djungarian hamster, *phodopus sungorus*. *Brain Res* 1993;609:45-50.
86. Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. *Neurosci Lett* 1989;97:140-4.
87. McArthur AJ, Gillette MU, Prosser RA. Melatonin directly resets the rat suprachiasmatic circadian clock in vitro. *Brain Res* 1991;565:158-61.
88. McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase c at dusk and dawn. *Endocrinology* 1997;138:627-34.
89. Hunt AE, Al-Ghoul WM, Gillette MU, et al. Activation of mt(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. *Am J Physiol Cell Physiol* 2001;280:C110-8.
90. Shirakawa T, Moore RY. Glutamate shifts the phase of the circadian neuronal firing rhythm in the rat suprachiasmatic nucleus in vitro. *Neurosci Lett* 1994;178:47-50.
91. Shibata S, Watanabe A, Hamada T, et al. N-methyl-d-aspartate induces phase shifts in circadian rhythm of neuronal activity of rat *scn* in vitro. *Am J Physiol* 1994;267:R360-4.
92. Watanabe A, Hamada T, Shibata S, et al. Effects of nitric oxide synthase inhibitors on n-methyl-d-aspartate-induced phase delay of circadian rhythm of neuronal activity in the rat suprachiasmatic nucleus in vitro. *Brain Res* 1994;646:161-4.



93. Watanabe A, Ono M, Shibata S, et al. Effect of a nitric oxide synthase inhibitor, n-nitro-l-arginine methylester, on light-induced phase delay of circadian rhythm of wheel-running activity in golden hamsters. *Neurosci Lett* 1995;192:25-8.
94. Weber ET, Gannon RL, Michel AM, et al. Nitric oxide synthase inhibitor blocks light-induced phase shifts of the circadian activity rhythm, but not c-fos expression in the suprachiasmatic nucleus of the syrian hamster. *Brain Res* 1995;692:137-42.
95. Ding JM, Buchanan GF, Tischkau SA, et al. A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock. *Nature* 1998;394:381-4.
96. Ding JM, Faiman LE, Hurst WJ, et al. Resetting the biological clock: Mediation of nocturnal creb phosphorylation via light, glutamate, and nitric oxide. *J Neurosci* 1997;17:667-75.
97. Tischkau SA, Mitchell JW, Tyan SH, et al. Ca<sup>2+</sup>/camp response element-binding protein (creb)-dependent activation of per1 is required for light-induced signaling in the suprachiasmatic nucleus circadian clock. *J Biol Chem* 2003;278:718-23.
98. Bradbury MJ, Dement WC, Edgar DM. Serotonin-containing fibers in the suprachiasmatic hypothalamus attenuate light-induced phase delays in mice. *Brain Res* 1997;768:125-34.
99. Mintz EM, Jasnow AM, Gillespie CF, et al. Gaba interacts with photic signaling in the suprachiasmatic nucleus to regulate circadian phase shifts. *Neuroscience* 2002;109:773-8.
100. Bergstrom AL, Hannibal J, Hindersson P, et al. Light-induced phase shift in the syrian hamster (*mesocricetus auratus*) is attenuated by the pacap receptor antagonist pacap6-38 or pacap immunoneutralization. *Eur J Neurosci* 2003;18:2552-62.
101. Chen D, Buchanan GF, Ding JM, et al. Pituitary adenylyl cyclase-activating peptide: A pivotal modulator of glutamatergic regulation of the suprachiasmatic circadian clock. *Proc Natl Acad Sci U S A* 1999;96:13468-73.
102. Tischkau SA, Gallman EA, Buchanan GF, et al. Differential camp gating of glutamatergic signaling regulates long-term state changes in the suprachiasmatic circadian clock. *J Neurosci* 2000;20:7830-7.
103. Zatz M, Brownstein MJ. Intraventricular carbachol mimics the effects of light on the circadian rhythm in the rat pineal gland. *Science* 1979;203:358-61.
104. Zatz M, Herkenham MA. Intraventricular carbachol mimics the phase-shifting effect of light on the circadian rhythm of wheel-running activity. *Brain Res* 1981;212:234-8.
105. Earnest DJ, Turek FW. Role for acetylcholine in mediating effects of light on reproduction. *Science* 1983;219:77-9.
106. Murakami N, Takahashi K, Kawashima K. Effect of light on the acetylcholine concentrations of the suprachiasmatic nucleus in the rat. *Brain Res* 1984;311:358-60.
107. Wenthold RJ. Glutamate and aspartate as neurotransmitters for the auditory nerve. In: DiChiara G, Gessa GL, editor: (eds). *Glutamate as a neurotransmitter*. New York: Raven Press; 1981. pp 69-78.
108. Yasuhara O, Tooyama I, Aimi Y, et al. Demonstration of cholinergic ganglion cells in rat retina: Expression of an alternative splice variant of choline acetyltransferase. *J Neurosci* 2003;23:2872-81.
109. Pauly JR, Horseman ND. Anticholinergic agents do not block light-induced circadian phase shifts. *Brain Res* 1985;348:163-7.
110. Colwell CS, Kaufman CM, Menaker M. Phase-shifting mechanisms in the mammalian circadian system: New light on the carbachol paradox. *J Neurosci* 1993;13:1454-9.
111. Liu C, Gillette MU. Cholinergic regulation of the suprachiasmatic nucleus circadian rhythm via a muscarinic mechanism at night. *J Neurosci* 1996;16:744-51.
112. Buchanan GF, Gillette MU. New light on an old paradox: Site-dependent effects of carbachol on circadian rhythms. *Exp Neurol* 2005;193:489-96.
113. Gillette MU, Buchanan GF, Artinian L, et al. Role of the m1 receptor in regulating circadian rhythms. *Life Sci* 2001;68:2467-72.
114. Welsh DK, Logothetis DE, Meister M, et al. Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. *Neuron* 1995;14:697-706.
115. Gallego M, Virshup DM. Post-translational modifications regulate the ticking of the circadian clock. *Nat Rev Mol Cell Biol* 2007;8:139-48.
116. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. *Hum Mol Genet* 2006;15 Spec No 2:R271-7.
117. Sato TK, Panda S, Miraglia LJ, et al. A functional genomics strategy reveals rora as a component of the mammalian circadian clock. *Neuron* 2004;43:527-37.

118. Barnes JW, Tischkau SA, Barnes JA, et al. Requirement of mammalian timeless for circadian rhythmicity. *Science* 2003;302:439-42.
119. Honma S, Kawamoto T, Takagi Y, et al. Dec1 and dec2 are regulators of the mammalian molecular clock. *Nature* 2002;419:841-4.
120. Asher G, Gatfield D, Stratmann M, et al. Sirt1 regulates circadian clock gene expression through per2 deacetylation. *Cell* 2008;134:317-28.
121. Nakahata Y, Kaluzova M, Grimaldi B, et al. The nad<sup>+</sup>-dependent deacetylase sirt1 modulates clock-mediated chromatin remodeling and circadian control. *Cell* 2008;134:329-40.
122. Harms E, Young MW, Saez L. Ck1 and gsk3 in the drosophila and mammalian circadian clock. *Novartis Found Symp* 2003;253:267-77; discussion 102-9, 277-84.
123. Martinek S, Inonog S, Manoukian AS, et al. A role for the segment polarity gene shaggy/gsk-3 in the drosophila circadian clock. *Cell* 2001;105:769-79.
124. Virshup DM, Eide EJ, Forger DB, et al. Reversible protein phosphorylation regulates circadian rhythms. *Cold Spring Harb Symp Quant Biol* 2007;72:413-20.
125. Harrisingh MC, Nitabach MN. Circadian rhythms. Integrating circadian timekeeping with cellular physiology. *Science* 2008;320:879-80.
126. Toh KL, Jones CR, He Y, et al. An hper2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 2001;291:1040-3.
127. Xu Y, Padiath QS, Shapiro RE, et al. Functional consequences of a ckidelta mutation causing familial advanced sleep phase syndrome. *Nature* 2005;434:640-4.
128. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. *Sleep* 2003;26:413-5.
129. Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. *EMBO Rep* 2001;2:342-6.
130. Archer SN, Viola AU, Kyriakopoulou V, et al. Inter-individual differences in habitual sleep timing and entrained phase of endogenous circadian rhythms of bmal1, per2 and per3 mrna in human leukocytes. *Sleep* 2008;31:608-17.
131. Katzenberg D, Young T, Finn L, et al. A clock polymorphism associated with human diurnal preference. *Sleep* 1998;21:569-76.
132. Mishima K, Tozawa T, Satoh K, et al. The 3111t/c polymorphism of hclock is associated with evening preference and delayed sleep timing in a japanese population sample. *Am J Med Genet B Neuropsychiatr Genet* 2005;133B:101-4.
133. Izumo M, Johnson CH, Yamazaki S. Circadian gene expression in mammalian fibroblasts revealed by real-time luminescence reporting: Temperature compensation and damping. *Proc Natl Acad Sci U S A* 2003;100:16089-94.
134. Ueda HR, Chen W, Adachi A, et al. A transcription factor response element for gene expression during circadian night. *Nature* 2002;418:534-9.
135. Welsh DK, Yoo SH, Liu AC, et al. Bioluminescence imaging of individual fibroblasts reveals persistent, independently phased circadian rhythms of clock gene expression. *Curr Biol* 2004;14:2289-95.
136. Yamaguchi S, Mitsui S, Miyake S, et al. The 5' upstream region of mper1 gene contains two promoters and is responsible for circadian oscillation. *Curr Biol* 2000;10:873-6.
137. Kuhlman SJ, Quintero JE, McMahon DG. Gfp fluorescence reports period 1 circadian gene regulation in the mammalian biological clock. *Neuroreport* 2000;11:1479-82.
138. Wilsbacher LD, Yamazaki S, Herzog ED, et al. Photocircadian expression of luciferase in mperiod1-luc transgenic mice in vivo. *Proc Natl Acad Sci U S A* 2002;99:489-94.
139. Yamazaki S, Numano R, Abe M, et al. Resetting central and peripheral circadian oscillators in transgenic rats. *Science* 2000;288:682-5.
140. Yoo SH, Yamazaki S, Lowrey PL, et al. Period2::Luciferase real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proc Natl Acad Sci U S A* 2004;101:5339-46.
141. Klein DC, Weller JL. Indole metabolism in the pineal gland: A circadian rhythm in n-acetyltransferase. *Science* 1970;169:1093-5.
142. Tosini G, Menaker M. Circadian rhythms in cultured mammalian retina. *Science* 1996;272:419-21.
143. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell* 1998;93:929-37.

144. Balsalobre A, Marcacci L, Schibler U. Multiple signaling pathways elicit circadian gene expression in cultured rat-1 fibroblasts. *Curr Biol* 2000;10:1291-4.
145. Brown SA, Zimbrunn G, Fleury-Olela F, et al. Rhythms of mammalian body temperature can sustain peripheral circadian clocks. *Curr Biol* 2002;12:1574-83.
146. Pando MP, Morse D, Cermakian N, et al. Phenotypic rescue of a peripheral clock genetic defect via *scn* hierarchical dominance. *Cell* 2002;110:107-17.
147. Yagita K, Tamanini F, van Der Horst GT, et al. Molecular mechanisms of the biological clock in cultured fibroblasts. *Science* 2001;292:278-81.
148. Abraham U, Prior JL, Granados-Fuentes D, et al. Independent circadian oscillations of *period1* in specific brain areas in vivo and in vitro. *J Neurosci* 2005;25:8620-6.
149. Granados-Fuentes D, Prolo LM, Abraham U, et al. The suprachiasmatic nucleus entrains, but does not sustain, circadian rhythmicity in the olfactory bulb. *J Neurosci* 2004;24:615-9.
150. Abe M, Herzog ED, Yamazaki S, et al. Circadian rhythms in isolated brain regions. *J Neurosci* 2002;22:350-6.
151. Yamazaki S, Straume M, Tei H, et al. Effects of aging on central and peripheral mammalian clocks. *Proc Natl Acad Sci U S A* 2002;99:10801-6.
152. Stokkan KA, Yamazaki S, Tei H, et al. Entrainment of the circadian clock in the liver by feeding. *Science* 2001;291:490-3.
153. Davidson AJ, Castanon-Cervantes O, Leise TL, et al. Visualizing jet lag in the mouse suprachiasmatic nucleus and peripheral circadian timing system. *Eur J Neurosci* 2009;29:171-80.
154. Honma S, Honma K, Hiroshige T. Dissociation of circadian rhythms in rats with a hypothalamic island. *Am J Physiol* 1984;246:R949-54.
155. Eskes GA, Rusak B. Horizontal knife cuts in the suprachiasmatic area prevent hamster gonadal responses to photoperiod. *Neurosci Lett* 1985;61:261-6.
156. Nunez AA, Brown MH, Youngstrom TG. Hypothalamic circuits involved in the regulation of seasonal and circadian rhythms in male golden hamsters. *Brain Res Bull* 1985;15:149-53.
157. Brown MH, Nunez AA. Hypothalamic circuits and circadian rhythms: Effects of knife cuts vary with their placement within the suprachiasmatic area. *Brain Res Bull* 1986;16:705-11.
158. Silver R, LeSauter J, Tresco PA, et al. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. *Nature* 1996;382:810-3.
159. Buijs RM, Markman M, Nunes-Cardoso B, et al. Projections of the suprachiasmatic nucleus to stress-related areas in the rat hypothalamus: A light and electron microscopic study. *J Comp Neurol* 1993;335:42-54.
160. Van der Beek EM, Horvath TL, Wiegant VM, et al. Evidence for a direct neuronal pathway from the suprachiasmatic nucleus to the gonadotropin-releasing hormone system: Combined tracing and light and electron microscopic immunocytochemical studies. *J Comp Neurol* 1997;384:569-79.
161. Vrang N, Larsen PJ, Mikkelsen JD. Direct projection from the suprachiasmatic nucleus to hypophysiotrophic corticotropin-releasing factor immunoreactive cells in the paraventricular nucleus of the hypothalamus demonstrated by means of phaseolus vulgaris-leucoagglutinin tract tracing. *Brain Res* 1995;684:61-9.
162. Bamshad M, Aoki VT, Adkison MG, et al. Central nervous system origins of the sympathetic nervous system outflow to white adipose tissue. *Am J Physiol* 1998;275:R291-9.
163. Buijs RM, Chun SJ, Nijijima A, et al. Parasympathetic and sympathetic control of the pancreas: A role for the suprachiasmatic nucleus and other hypothalamic centers that are involved in the regulation of food intake. *J Comp Neurol* 2001;431:405-23.
164. Buijs RM, la Fleur SE, Wortel J, et al. The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. *J Comp Neurol* 2003;464:36-48.
165. la Fleur SE, Kalsbeek A, Wortel J, et al. Polysynaptic neural pathways between the hypothalamus, including the suprachiasmatic nucleus, and the liver. *Brain Res* 2000;871:50-6.
166. Nijijima A, Nagai K, Nagai N, et al. Light enhances sympathetic and suppresses vagal outflows and lesions including the suprachiasmatic nucleus eliminate these changes in rats. *J Auton Nerv Syst* 1992;40:155-60.
167. Scheer FA, Ter Horst GJ, van Der Vliet J, et al. Physiological and anatomic evidence for regulation of the heart by suprachiasmatic nucleus in rats. *Am J Physiol Heart Circ Physiol* 2001;280:H1391-9.
168. Tousson E, Meissl H. Suprachiasmatic nuclei grafts restore the circadian rhythm in the paraventricular nucleus of the hypothalamus. *J Neurosci* 2004;24:2983-8.

169. Guo H, Brewer JM, Champhekar A, et al. Differential control of peripheral circadian rhythms by suprachiasmatic-dependent neural signals. *Proc Natl Acad Sci U S A* 2005;102:3111-6.
170. Allen G, Rappe J, Earnest DJ, et al. Oscillating on borrowed time: Diffusible signals from immortalized suprachiasmatic nucleus cells regulate circadian rhythmicity in cultured fibroblasts. *J Neurosci* 2001;21:7937-43.
171. Guo H, Brewer JM, Lehman MN, et al. Suprachiasmatic regulation of circadian rhythms of gene expression in hamster peripheral organs: Effects of transplanting the pacemaker. *J Neurosci* 2006;26:6406-12.
172. Hatcher NG, Atkins N, Jr., Annangudi SP, et al. Mass spectrometry-based discovery of circadian peptides. *Proc Natl Acad Sci U S A* 2008;105:12527-32.
173. Lee JE, Atkins N, Jr., Hatcher NG, et al. Endogenous peptide discovery of the rat circadian clock: A focused study of the suprachiasmatic nucleus by ultrahigh performance tandem mass spectrometry. *Mol Cell Proteomics* 2010;9:285-97.
174. Aton SJ, Colwell CS, Harmar AJ, et al. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. *Nat Neurosci* 2005;8:476-83.
175. Brown TM, Colwell CS, Waschek JA, et al. Disrupted neuronal activity rhythms in the suprachiasmatic nuclei of vasoactive intestinal polypeptide-deficient mice. *J Neurophysiol* 2007;97:2553-8.
176. Gillette MU, Reppert SM. The hypothalamic suprachiasmatic nuclei: Circadian patterns of vasopressin secretion and neuronal activity in vitro. *Brain Res Bull* 1987;19:135-9.
177. Hatton GI. Emerging concepts of structure-function dynamics in adult brain: The hypothalamo-neurohypophysial system. *Prog Neurobiol* 1990;34:437-504.
178. Piggins HD, Antle MC, Rusak B. Neuropeptides phase shift the mammalian circadian pacemaker. *J Neurosci* 1995;15:5612-22.
179. Reppert SM, Artman HG, Swaminathan S, et al. Vasopressin exhibits a rhythmic daily pattern in cerebrospinal fluid but not in blood. *Science* 1981;213:1256-7.
180. Reppert SM, Perlow MJ, Artman HG, et al. The circadian rhythm of oxytocin in primate cerebrospinal fluid: Effects of destruction of the suprachiasmatic nuclei. *Brain Res* 1984;307:384-7.
181. Kramer A, Yang FC, Snodgrass P, et al. Regulation of daily locomotor activity and sleep by hypothalamic egf receptor signaling. *Science* 2001;294:2511-5.
182. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. *Nature* 2002;417:405-10.
183. Cailotto C, La Fleur SE, Van Heijningen C, et al. The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: Are the clock genes involved? *Eur J Neurosci* 2005;22:2531-40.
184. Knutsson A. Health disorders of shift workers. *Occup Med (Lond)* 2003;53:103-8.
185. Mahoney MM. Shift work, jet lag, and female reproduction. *Int J Endocrinol* 2010;2010:813764.
186. Megdal SP, Kroenke CH, Laden F, et al. Night work and breast cancer risk: A systematic review and meta-analysis. *Eur J Cancer* 2005;41:2023-32.
187. Davidson AJ, Sellix MT, Daniel J, et al. Chronic jet-lag increases mortality in aged mice. *Curr Biol* 2006;16:R914-6.

### **Figure Legends**

**Figure 1.** Anatomy of the mammalian suprachiasmatic nucleus (SCN). This medial, transverse section of the rat anterior hypothalamus shows the bilateral SCN stained darkly with an antibody to an endogenous peptide. The paired SCN are at the base of the brain, flanking the third ventricle (3V) and positioned directly above the optic chiasm (OC). The major subdivisions of the SCN are delineated. The dorsomedial SCN (DM) is marked by neurons expressing arginine vasopressin (AVP), whereas neurons of the ventrolateral SCN (VL) express vasoactive intestinal peptide (VIP). A central region contains neurons that express gastrin-releasing peptide (GRP) and little SAAS.

**Figure 2.** Circadian organization of temporal windows of SCN sensitivity to phase-resetting signals transmitted from various brain sites. Time-of-day specific signals are presented together with the major sources of SCN innervation by projections bearing these neurotransmitters and neuropeptides. Daytime is marked by sensitivity to serotonin (5-HT), pituitary adenylate cyclase-activating peptide (PACAP), neuropeptide Y (NYP) and GABA. During dusk and dawn, the pineal hormone melatonin can stimulate resetting of the

SCN clock. At night, the SCN is sensitive to phase adjustment by glutamate and PACAP from the eye, as well as by cholinergic inputs from brain regions that regulate sleep and wakefulness.